Figure 6
Rapamycin attenuated lung inflammation through down-regulation of phosphorylated mTORC1.
(A) Body weight changes in the LPS challenged mice treated with or without rapamycin. (B) Inflammatory cells in the BALF of mice treated with or without rapamycin. (C) Inflammatory mediators in the BALF of mice treated with or without rapamycin. (D) Th17-linear cytokines including IL-17 and IL-22 in the BALF of mice treated with or without rapamycin. (E) Weston blot analysis tested the protein level of phosphorylated mTORC1. (F) Immunohistochemistry analysis tested the protein level of phosphorylated mTORC1. The tan color indicates Ser2448pmTORC1-positive staining. R: rapamycin; L: LPS; C: control; I.T.: intratracheal. The mice were harvested on D2. *p < 0.05, compared with LPS treated group. Error bars indicate SEM. All mice were wild type, with 3~5 mice per group.
